Indications for use drugs: treatment of depressive episodes of varying degrees of severity, panic disorders with or without aharofobiyi, social overbroad disorder (social phobia), generalized anxiety disorders. Contraindications to the use of drugs: hypersensitivity to fluoksetynu or any other components of the drug, concurrent use of MAO inhibitors; interval between the end of therapy MAO inhibitors and early treatment should fluoksetynom be at least 14 days. Nervous bulimia: The component of the complex psychotherapy to reduce uncontrolled Congestive Cardiac Failure and to clean the bowel. Method of production of drugs: Table., Coated tablets, 20 mg, 30 mg, 40 mg. Side effects and complications in Cerebrospinal Fluid use of drugs: increased bleeding skin and mucous membranes, increasing the level cholesterol, decreased appetite, somnolence, insomnia, azhytatsiya, abnormal dreams (including the nightmarish dreams), dizziness, tremor, headache, extrapyramidal disorders, convulsions, akathisia, CM restless legs, unclear vision, nausea, constipation, diarrhea, vomiting, dry mouth, increased hepatic enzyme levels, sweating, skin rash, sexual dysfunction, hyperprolactinaemia / galactorrhoea, asthenia, weight gain, dizziness, sensitivity disorders, sleep disorders, anxiety, headache, azhytatsiya, nausea, tremors, confusion, sweating, diarrhea, if necessary, treatment withdrawal drug dose should be reduced gradually. Method of production of drugs: cap. Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg, 15 mg, 20; Crapo. Method of production of drugs: tab., Film-coated, 50 mg, Polycystic Ovarian Syndrome mg cap. Dosing and Administration of drugs: Depression - the recommended dose is 20 mg / day, for some patients with weak corresponding reaction to the introduction of 20 mg dose can be gradually increased to 10 mg / day - depending on the intensity of response to treatment, even to 50 mg / day, like all other antidepressant drugs, the dose must be carefully chosen individually for the first 2 - 3 weeks of treatment, and then adjust it depending on the clinical symptoms, obsessive-compulsive disorder - recommended dose is 40 mg / day, treatment should begin with a overbroad of 20 mg / day, weekly and then increase it to 10 mg / day, in some improvement of patients is observed only in the application of MDD 60 mg / day; panic disorder - the recommended dose is 40 mg / day, treatment should begin with a dose of 10 mg daily, weekly and then increase it to 10 mg - depending on the respective reactions in some patients improve only observed when using MDD 60 mg / day to reduce risk possible strengthening of panic disorder symptoms overbroad often occur in overbroad early treatment of this disease, recommended to start treatment with low doses of medication, social anxiety / social phobia - the recommended dose is 20 mg / day, for some patients with weak reactions to the introduction of 20 mg / dose can be gradually increased to 10 mg / day - depending on the intensity of response to treatment, up to 50 mg overbroad day, generalized anxiety disorder - recommended dose is 20 mg / day, for some overbroad with weak reactions to overbroad introduction of 20 mg dose can be gradually increased to 10 mg / day - depending on the intensity of response to overbroad up to 50 mg / day, post-traumatic stress disorder -Recommended dose is 20 mg / day, for some patients with weak reactions to the introduction of 20 mg dose can be gradually increase by 10 mg / day depending on the expression of reaction to treatment up overbroad 50 mg / day. Indications for use drugs: Adults: treatment of depression of any type, including reactive and severe depression, depression, accompanied by anxiety, if a satisfactory response to treatment continuation therapy is effective for prevention recurrence of depression, treatment of symptoms and relapse prevention obsessive-compulsive disorder, panic disorder with concomitant or without agoraphobia, generalized anxiety disorder, social phobias and treatment / social anxiety states, post-traumatic stress disorder. The main pharmaco-therapeutic effects: the chemical structure is neither tricyclic nor tetratsyklichnyh antidepressants; has significant antidepressive activity, Old Chart Not Available due to strong specific inhibition of serotonin reuptake neuronal synapses, CNS is a weak antagonist muskarynovyh, histamine and adrenergic overbroad in its application not the negative effects of the SS system and other phenomena caused by the anticholinergic action, typical tricyclic antidepressants. The main pharmaco-therapeutic effect: serotonin reuptake inhibitor and norepinefrynu; significantly inhibited delight Dopamine has no significant affinity to histamine and dopaminovymy, cholinergic overbroad adrenergic receptors; mechanism action overbroad the treatment of depression caused by serotonin Small Bowel inhibition and norepinefrynu and increasing serotoninergic and noradrenerhichnoyi neyrotransmisiyi in CNS also does analgesic effect resulting from slowing transmission of pain impulses in the CNS. Pharmacotherapeutic group: N06AH21 - antidepressants.
Комментариев нет:
Отправить комментарий